ClinicalTrials.gov record
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
UNKNOWN · NCT01094964
Trial record
NCT IDNCT01094964
Status
UNKNOWN
Study type
INTERVENTIONAL
Phase
PHASE3
Enrollment
242
Conditions
Bladder Cancer
Interventions
BCG solution, recombinant interferon alfa, epirubicin hydrochloride, mitomycin C, laboratory biomarker analysis, hyperthermia treatment, quality-of-life assessment
Locations
Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom, Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom, Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom, University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom, St. George's Hospital, London, England, United Kingdom, University College of London Hospitals, London, England, United Kingdom, South Manchester University Hospital, Manchester, England, United Kingdom, James Cook University Hospital, Middlesbrough, England, United Kingdom
Indexed topics
Last update
2013-08-09